Display options
Cite
Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166-74doi: 10.1002/wps.20309.
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016). Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World psychiatry : official journal of the World Psychiatric Association (WPA), 15(2), 166-74. https://doi.org/10.1002/wps.20309
Vancampfort, Davy, et al. "Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis." World psychiatry : official journal of the World Psychiatric Association (WPA) vol. 15,2 (2016): 166-74. doi: https://doi.org/10.1002/wps.20309
Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016 Jun;15(2):166-74. doi: 10.1002/wps.20309. PMID: 27265707; PMCID: PMC4911762.
Copy Download .nbib Format: NLM
Share it on

World Psychiatry. 2016 Jun;15(2):166-74. doi: 10.1002/wps.20309.

Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.

World psychiatry : official journal of the World Psychiatric Association (WPA)

Davy Vancampfort, Christoph U Correll, Britta Galling, Michel Probst, Marc De Hert, Philip B Ward, Simon Rosenbaum, Fiona Gaughran, John Lally, Brendon Stubbs

Affiliations

  1. KU Leuven - University of Leuven, Department of Rehabilitation Sciences, Leuven, Belgium.
  2. KU Leuven - University of Leuven, Z.org KU Leuven, Kortenberg, Belgium.
  3. Zucker Hillside Hospital, Glen Oaks, NY, USA.
  4. Hofstra North Shore LIJ School of Medicine, Hempstead, NY, USA.
  5. School of Psychiatry and Ingham Institute of Applied Medical Research, University of New South Wales, Sydney, Australia.
  6. Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK.
  7. Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK.
  8. Health Service and Population Research Department, Institute of Psychiatry, King's College London, London, UK.

PMID: 27265707 PMCID: PMC4911762 DOI: 10.1002/wps.20309

Abstract

Type 2 diabetes mellitus (T2DM) is highly predictive of cardiovascular diseases and can have particularly deleterious health impacts in people with severe mental illness (SMI), i.e. schizophrenia, bipolar disorder or major depressive disorder. This meta-analysis aimed: a) to describe pooled frequencies of T2DM in people with SMI; b) to analyze the influence of demographic, illness and treatment variables as well as T2DM assessment methods; and c) to describe T2DM prevalence in studies directly comparing persons with each specific SMI diagnosis to general population samples. The trim and fill adjusted pooled T2DM prevalence among 438,245 people with SMI was 11.3% (95% CI: 10.0%-12.6%). In antipsychotic-naïve participants, the prevalence of T2DM was 2.9% (95% CI: 1.7%-4.8%). There were no significant diagnostic subgroup differences. A comparative meta-analysis established that multi-episode persons with SMI (N=133,470) were significantly more likely to have T2DM than matched controls (N=5,622,664): relative risk, RR=1.85, 95% CI: 1.45-2.37, p<0.001. The T2DM prevalence was consistently elevated in each of the three major diagnostic subgroups compared to matched controls. Higher T2DM prevalences were observed in women with SMI compared to men (RR=1.43, 95% CI: 1.20-1.69, p<0.001). Multi-episode (versus first-episode) status was the only significant predictor for T2DM in a multivariable meta-regression analysis (r(2) =0.52, p<0.001). The T2DM prevalence was higher in patients prescribed antipsychotics, except for aripriprazole and amisulpride. Routine screening and multidisciplinary management of T2DM is needed. T2DM risks of individual antipsychotic medications should be considered when making treatment choices.

© 2016 World Psychiatric Association.

Keywords: Diabetes mellitus; antipsychotics; bipolar disorder; major depressive disorder; schizophrenia; severe mental illness

References

  1. J Psychopharmacol. 2010 Nov;24(4 Suppl):69-80 - PubMed
  2. Psychopharmacology (Berl). 2013 Jun;227(3):467-77 - PubMed
  3. Neuropsychopharmacology. 2010 Aug;35(9):1997-2004 - PubMed
  4. Acta Psychiatr Scand. 2015 Aug;132(2):144-57 - PubMed
  5. World Psychiatry. 2011 Jun;10(2):138-51 - PubMed
  6. Ann Clin Psychiatry. 2012 Feb;24(1):69-81 - PubMed
  7. Br J Psychiatry. 2011 Aug;199(2):99-105 - PubMed
  8. Lancet. 2010 Jun 26;375(9733):2215-22 - PubMed
  9. J Clin Psychiatry. 2015 Nov;76(11):1490-9 - PubMed
  10. Biometrics. 1994 Dec;50(4):1088-101 - PubMed
  11. World Psychiatry. 2015 Oct;14(3):339-47 - PubMed
  12. World Psychiatry. 2011 Feb;10(1):52-77 - PubMed
  13. Circulation. 1999 Sep 7;100(10):1134-46 - PubMed
  14. Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26 - PubMed
  15. Ann Pharmacother. 2008 Sep;42(9):1316-22 - PubMed
  16. Psychiatr Serv. 2012 Jan;63(1):83-6 - PubMed
  17. Depress Anxiety. 2015 Oct;32(10):763-73 - PubMed
  18. Acta Psychiatr Scand. 2013 Mar;127(3):195-201 - PubMed
  19. World Psychiatry. 2014 Jun;13(2):189-92 - PubMed
  20. Br J Psychiatry. 2010 Oct;197(4):266-71 - PubMed
  21. Lancet. 2012 Dec 15;380(9859):2197-223 - PubMed
  22. JAMA. 2000 Apr 19;283(15):2008-12 - PubMed
  23. Eur Psychiatry. 2009 Sep;24(6):412-24 - PubMed
  24. World Psychiatry. 2014 Jun;13(2):153-60 - PubMed
  25. J Clin Psychopharmacol. 2012 Apr;32(2):261-5 - PubMed
  26. Arch Gen Psychiatry. 2007 Oct;64(10):1123-31 - PubMed
  27. Psychiatry Res. 2012 Dec 30;200(2-3):73-8 - PubMed
  28. Acta Psychiatr Scand. 2015 Aug;132(2):86-96 - PubMed
  29. Psychiatry Clin Neurosci. 2013 Sep;67(6):451-6 - PubMed
  30. Psychol Med. 2015;45(12):2619-29 - PubMed
  31. Disabil Rehabil. 2012;34(1):1-12 - PubMed
  32. PLoS One. 2011;6(5):e19590 - PubMed
  33. World Psychiatry. 2015 Jun;14(2):119-36 - PubMed
  34. Mol Psychiatry. 2013 Jun;18(6):692-9 - PubMed
  35. J Clin Psychiatry. 2010;71 Suppl E1:e04 - PubMed
  36. Br J Psychiatry. 2012 Dec;201(6):435-43 - PubMed
  37. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  38. World Psychiatry. 2013 Oct;12(3):240-50 - PubMed
  39. Curr Pharm Des. 2012;18(36):5900-19 - PubMed
  40. Psychol Med. 2012 Jan;42(1):125-47 - PubMed
  41. World Psychiatry. 2015 Feb;14(1):56-63 - PubMed
  42. J Clin Psychiatry. 2014 May;75(5):e424-40 - PubMed
  43. BMJ. 2013 May 21;346:f2539 - PubMed
  44. Schizophr Bull. 2015 May;41(3):664-73 - PubMed
  45. Br J Psychiatry. 2009 Jun;194(6):491-9 - PubMed
  46. PLoS Med. 2009 Jul 21;6(7):e1000097 - PubMed

Publication Types